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Abstract 
Introduction: Considering the limitations of screening with nalidixic acid to detect reduced susceptibility to fluoroquinolones of Salmonella 
enterica serovar Typhi (S.Typhi) strains, we evaluated the use of a 30 µg nalidixic acid disc screening method in Pakistan. 
Methodology: Non duplicate nalidixic acid susceptible S. Typhi isolates (246) from 2003-2008 were retrieved from the Salmonella strain 
bank. Minimum inhibitory concentrations of ciprofloxacin for all strains were determined by agar dilution and further rechecked by 
ciprofloxacin E-tests.E. coli ATCC 25922 was used as the control strain. The MIC data for ciprofloxacin were compared with nalidixic acid 
disk (30µg) zone diameters. 
Results: Repeat testing of all S. Typhi isolates with a nalidixic acid (30µg) disk showed 100% susceptibility with an average zone diameter of 
26 mm. Agar dilution testing revealed reduced susceptibility to ciprofloxacin, with MICs of 0.125 µg /ml for three (1.2%) isolates only. Zone 
sizes of strains with higher MICs were significantly lower than the strains with lower MICs (20 versus 26 mm) (p value <0.001). 
Conclusion: Estimation of fluoroquinolone MICs on every nalidixic acid susceptible S. Typhi strain is not cost effective in our setting; the 
proportion of strains with high fluoroquinolone MICs was found to be very low. We recommend periodic fluoroquinolone MIC 
determination to include all isolates with a nalidixic acid borderline zone (size 20-22 mm). 
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Introduction 
Fluoroquinolones have been recommended by 
World Health Organization (WHO) as empirical 
therapy for the management of multidrug resistant 
enteric fever [1]. Globally the spread of Salmonella 
enterica serovar Typhi (S. Typhi) strains with 
fluoroquinolone reduced susceptibility has become a 
major problem [2,3]. Current Clinical Laboratory 
Standards Institute (CLSI) break points for reporting 
fluoroquinolone susceptibility in Enterobacteriaceae 
do not detect these strains [4]. By using a disk 
diffusion method, usually these strains appear resistant 
when tested with a nalidixic acid disk (30 µg) and 
therefore screening with it is a sensitive, specific and 
cost-effective approach, used by many laboratories in 
resource-limited countries [5]. 
Pakistan is a high burden country for typhoid fever 
with an annual incidence of 412.9/100,000 person 
years [6]. Optimal detection of endemic strains with 
reduced susceptibility to fluoroquinolones, for 
example, ciprofloxacin MIC ≥ 0.125 or ofloxacin [6], 
is crucial as this drug is frequently used by family 
physicians for the management of typhoid. Emergence 
of strains with reduced susceptibility to 
fluoroquinolone has led to treatment failure, as 
previously reported in regional and local studies [7,8)]. 
The method of screening with nalidixic acid has been 
validated and reported to be efficient for endogenous 
isolates and is currently in use by many laboratories in 
Pakistan [9,10]. However the recent emergence of 
nalidixic acid susceptible S. Typhi strains with high 
fluoroquinolone minimum inhibitory concentration 
(MIC) is of great concern [11-14]. According to recent 
publications, the majority of reported nalidixic acid 
susceptible and fluoroquinolone resistant strains 
originated from India, Pakistan or Bangladesh [12]. 
This finding is alarming as it questions the validity of 
the nalidixic acid screening test and could lead to 
underreporting of fluoroquinolone resistance, resulting 
in clinical failure. In view of reports of emergence of 
these discordant strains, we reevaluated the 
fluoroquinolone MICs of nalidixic acid susceptible 
local S. Typhi strains with an aim to assess the current 
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utilization of the nalidixic acid screening method in 
our setup. 
 
Methodology 
This study was conducted in a clinical 
microbiology laboratory of the Aga Khan University, 
Karachi, Pakistan (AKU). The university and its 
laboratory have Joint Commission International 
accreditation (JCIA). The laboratory routinely 
participates in external quality control surveys with the 
College of American Pathologists (CAP). The clinical 
microbiology laboratory of AKU receives on the 
whole 400,000 specimens/year from both inpatients 
and outpatients from clinics and hospitals within the 
city as well as from all over the country via laboratory 
collection points in 50 major cities and towns of 
Pakistan. 
For the current study a total of 246, non-duplicate, 
nalidixic acid susceptible bacteremic isolates of S. 
Typhi were selected by convenience sampling and 
retrieved from the Salmonella strain bank and saved at 
-80°C.  The laboratory Salmonella bank is comprised 
of both nalidicic acid disk susceptible and resistant 
isolates. Out of those, only nalidixic acid disk 
susceptible isolates were chosen. All isolates were 
previously reported as fluoroquinolone susceptible 
based on nalidixic acid disk (30µg) screening. Out of 
these 246 isolates, 26 were retrieved from year 2003, 
164 from 2004, 27 from 2005, 7 from 2006, 12 from 
2007, and 10 from 2008. These strains were first 
cultured on MacConkey’s agar. The repeat 
identification and serotyping were done using standard 
procedures [15].  The susceptibility of all isolates to 
nalidixic acid was reevaluated using a 30 µg nalidixic 
acid disk [4] and zone diameters of ≤ 13 were 
considered as sensitive,, 14-18 were considered as 
intermediate, and ≥ 19 mm were considered as 
resistant [3]. The MIC of ciprofloxacin was 
determined using the agar dilution method. Isolates 
with ciprofloxacin MIC of ≤ 0.06 µg /ml were 
considered as susceptible while isolates with MIC of ≥ 
0.125 µg /ml were considered as having reduced 
susceptibility to fluoroquinolones [16]. Isolates with 
MIC of ≥ 0.125 µg /ml were further confirmed by 
using Etest (AB Bio disk).  E. coli ATCC 25922 was 
used as the control strain. 
 
Results 
Repeat testing of 246 S. Typhi isolates using a 
nalidixic acid (30 µg) disk showed nalidixic acid 
susceptibility of all strains with an average zone 
diameter of 26 mm (ranged between 20-33 mm). A 
total of 175 isolates (71%) showed a ciprofloxacin 
MIC of ≤ 0.03µg/ml and an average zone diameter of 
27 mm with a nalidixic acid (30 µg) disk. Sixty-eight 
S. Typhi isolates (27.6%) showed MIC of 0.06 µg /ml 
with an average zone size of 25 mm, and only three 
isolates (1.2%) had MIC considered to represent 
reduced susceptibility (0.125 µg /ml and an average 
zone size of 20 mm). As shown in the Figure, two of 
Figure 1. 
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the reduced susceptibility isolates belonged to year 
2005, and one to year 2006. The mean zone of the 
strains with ciprofloxacin MIC of 0.125 µg /ml was 
significantly lower than the mean zone sizes of strains 
with low MICs (p value < 0.001) as shown in the 
Table. 
 
Discussion 
This study confirms the emergence of nalidixic 
acid susceptible S. Typhi isolates with fluoroquinolone 
reduced susceptibility in Pakistan. Studies from the 
United Kingdom, United States, and Kuwait [11-13] 
reported a higher percentage of discordant nalidixic 
acid and ciprofloxacin susceptibility results in their 
Southeast Asian immigrants or travellers (i.e., 7%, 
12.5%, and 13.8%). Cooke et al. report 5% S. Typhi 
isolates from Pakistan with discordant results [14]. An 
Indian study also reported detection of such isolates 
[17]. All of the above studies mentioned the 
emergence of such ciprofloxacin resistance strains 
during the years 2000 to 2003. Our data shows 
isolation of such stains in the years 2005 and 2006 and 
a previously published study from our centre also had 
demonstrated absence of these strains in the years 
2002 to 2003 [9]. 
In the current study, isolates with reduced 
susceptibility to ciprofloxacin were not evaluated for 
underlying resistance mechanisms. However, recent 
studies have found that a fluoroquinolone resistance 
mechanism in nalidixic acid susceptible strains is 
plasmid mediated, which encodes transferable 
resistance to quinolones via the qnr gene. The qnr 
gene product has been demonstrated to directly protect 
DNA gyrase from quinolone inhibition [18]. 
A recent study evaluated the role of zone diameter 
measurement of various quinolone containing disks as 
a screening test for detecting this kind of resistance 
[18]. The results of that study showed that, with regard 
to newer mechanisms of ciprofloxacin resistance, the 
nalidixic acid zone diameter (30 µg disk) as well as 
MIC has poor correlation with raised ciprofloxacin 
MIC. However, our strains with higher MICs had 
significantly lower zone sizes than the strains with 
lower MICs, suggesting an alternative mechanism. 
This finding could be extremely important in guiding 
us to perform MICs in those S. Typhi isolates that are 
nalidixic acid susceptible but have a border line zone 
size (20-21 mm). 
The clinical relevance of these strains was not 
evaluated in any of the previous studies [11-13]; 
however, one can assume therapeutic failure in these 
cases, as also seen with the nalidixic acid resistant 
strains with decreased ciprofloxacin susceptibility 
[19]. 
Keeping in view the low isolation rate of these 
strains in our study, evaluation of ciprofloxacin MICs 
on every nalidixic acid susceptible strain would not be 
cost effective in a local setup. 
Recently, the use of a low concentration of 
ciprofloxacin disks (1 µg) has been proposed for better 
screening of S. Typhi isolates with a resistance 
mutation [18]. Any isolate showing nalidixic acid 
susceptibility with resistance by a 1 µg ciprofloxacin 
disk would be further checked for ciprofloxacin MIC. 
We did not use this tool; however, in view of the threat 
of further increase in discordant strains, this screening 
tool could possibly be used routinely in low-income 
countries. 
Alternatively, we propose that local clinical 
laboratories should continue nalidixic acid screening 
with periodic ciprofloxacin MIC determination in 
nalidixic acid susceptible S. Typhi isolates to evaluate 
any changing trend. In addition, MIC analysis should 
also be performed for those nalidixic acid susceptible 
Table. Ciprofloxacin MIC results and their correlation with nalidixic acid zone sizes in S. 
Typhi isolates (N = 246).  
MIC ranges for 
Ciprofloxacin 
(µg/mL)  
Number of organisms (%) 
 
Zone size (mm)  
(Nalidixic acid disk 30µg) 
Mean (±SD) 
≤0.03 175 (71.1) 27 (2.0) 
0.06 68 (27.6) 25(2.2) 
0.125 3 (1.2) 20 (0.5)* 
0.25 0 0 (0) 
Total number of isolates = 246 
*p<0.001 when compared isolates with MIC (≤0.03-0.06 µg/mL). P-value calculated through student’s t-test. 
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S. Typhi isolates showing treatment failure after a 
sufficient period of therapy. 
The strength of this report is that this is the first 
study determining ciprofloxacin MICs from this region 
on a large number of nalidixic acid susceptible isolates 
to detect the emergence of ciprofloxacin reduced 
susceptible strains. Our findings would be of interest 
not only at the regional level but also internationally as 
travellers, immigrants and refugees may acquire 
typhoid in Pakistan and travel to developed countries 
[20]. Our limitation was non-uniformity in the yearly 
distribution of isolates. 
 
Conclusion 
Currently, the evaluation of fluoroquinolone MICs 
in nalidixic acid susceptible S. Typhi isolates is neither 
required nor cost effective in our setting. It should be 
performed periodically and include all isolates of S. 
Typhi with a nalidixic acid zone of less than 21 mm. 
We also recommend the reevaluation of breakpoints 
for S. Typhi by CLSI with the aim of minimizing the 
cost as well as error of MIC reporting in resource-
limited countries where the disease is highly endemic 
and availability of trained staff and money are major 
issues. 
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